Literature DB >> 33326705

Retrospective Analysis Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation Offers Improvements in Efficiency of the Design of Volunteer Infection Studies for Antimalarial Drug Development.

Kayla Ann Andrews1,2, Joel S Owen1, James McCarthy3, David Wesche4, Nathalie Gobeau5, Thaddeus H Grasela1, Jörg J Möhrle5.   

Abstract

Volunteer infection studies using the induced blood stage malaria (IBSM) model have been shown to facilitate antimalarial drug development. Such studies have traditionally been undertaken in single-dose cohorts, as many as necessary to obtain the dose-response relationship. To enhance ethical and logistic aspects of such studies, and to reduce the number of cohorts needed to establish the dose-response relationship, we undertook a retrospective in silico analysis of previously accrued data to improve study design. A pharmacokinetic (PK)/pharmacodynamic (PD) model was developed from initial fictive-cohort data for OZ439 (mixing the data of the three single-dose cohorts as: n = 2 on 100 mg, 2 on 200 mg, and 4 on 500 mg). A three-compartment model described OZ439 PKs. Net growth of parasites was modeled using a Gompertz function and drug-induced parasite death using a Hill function. Parameter estimates for the PK and PD models were comparable for the multidose single-cohort vs. the pooled analysis of all cohorts. Simulations based on the multidose single-cohort design described the complete data from the original IBSM study. The novel design allows for the ascertainment of the PK/PD relationship early in the study, providing a basis for rational dose selection for subsequent cohorts and studies.
© 2020 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33326705      PMCID: PMC7993277          DOI: 10.1111/cts.12934

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.689


  13 in total

1.  Ways to fit a PK model with some data below the quantification limit.

Authors:  S L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

2.  Efficiencies of platform clinical trials: A vision of the future.

Authors:  Benjamin R Saville; Scott M Berry
Journal:  Clin Trials       Date:  2016-02-17       Impact factor: 2.486

3.  Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both.

Authors:  Janet Woodcock; Lisa M LaVange
Journal:  N Engl J Med       Date:  2017-07-06       Impact factor: 91.245

4.  First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials.

Authors:  Joerg J Moehrle; Stephan Duparc; Christoph Siethoff; Paul L M van Giersbergen; J Carl Craft; Sarah Arbe-Barnes; Susan A Charman; Maria Gutierrez; Sergio Wittlin; Jonathan L Vennerstrom
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

5.  A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs.

Authors:  James S McCarthy; Silvana Sekuloski; Paul M Griffin; Suzanne Elliott; Nanette Douglas; Chris Peatey; Rebecca Rockett; Peter O'Rourke; Louise Marquart; Cornelius Hermsen; Stephan Duparc; Jörg Möhrle; Katharine R Trenholme; Andrew J Humberstone
Journal:  PLoS One       Date:  2011-08-22       Impact factor: 3.240

6.  Comparison of statistical models to estimate parasite growth rate in the induced blood stage malaria model.

Authors:  Leesa F Wockner; Isabell Hoffmann; Peter O'Rourke; James S McCarthy; Louise Marquart
Journal:  Malar J       Date:  2017-08-25       Impact factor: 2.979

7.  Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.

Authors:  James S McCarthy; Julie Lotharius; Thomas Rückle; Stephan Chalon; Margaret A Phillips; Suzanne Elliott; Silvana Sekuloski; Paul Griffin; Caroline L Ng; David A Fidock; Louise Marquart; Noelle S Williams; Nathalie Gobeau; Lidiya Bebrevska; Maria Rosario; Kennan Marsh; Jörg J Möhrle
Journal:  Lancet Infect Dis       Date:  2017-03-28       Impact factor: 25.071

8.  Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development.

Authors:  James S McCarthy; Louise Marquart; Silvana Sekuloski; Katharine Trenholme; Suzanne Elliott; Paul Griffin; Rebecca Rockett; Peter O'Rourke; Theo Sloots; Iñigo Angulo-Barturen; Santiago Ferrer; María Belén Jiménez-Díaz; María-Santos Martínez; Rob Hooft van Huijsduijnen; Stephan Duparc; Didier Leroy; Timothy N C Wells; Mark Baker; Jörg J Möhrle
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

9.  A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study.

Authors:  James S McCarthy; Thomas Rückle; Elhadj Djeriou; Cathy Cantalloube; Daniel Ter-Minassian; Mark Baker; Peter O'Rourke; Paul Griffin; Louise Marquart; Rob Hooft van Huijsduijnen; Jörg J Möhrle
Journal:  Malar J       Date:  2016-09-13       Impact factor: 2.979

10.  Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion-451840 in an induced blood stage malaria study in healthy subjects.

Authors:  Andreas Krause; Jasper Dingemanse; Alexandre Mathis; Louise Marquart; Jörg J Möhrle; James S McCarthy
Journal:  Br J Clin Pharmacol       Date:  2016-05-11       Impact factor: 4.335

View more
  1 in total

Review 1.  Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.

Authors:  Craig R Rayner; Patrick F Smith; David Andes; Kayla Andrews; Hartmut Derendorf; Lena E Friberg; Debra Hanna; Alex Lepak; Edward Mills; Thomas M Polasek; Jason A Roberts; Virna Schuck; Mark J Shelton; David Wesche; Karen Rowland-Yeo
Journal:  Clin Pharmacol Ther       Date:  2021-03-09       Impact factor: 6.875

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.